Literature DB >> 28844946

Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.

Gabriela Rondón1, Rima M Saliba1, Julianne Chen1, Celina Ledesma1, Amin M Alousi1, Betul Oran1, Chitra M Hosing1, Partow Kebriaei1, Issa F Khouri1, Elizabeth J Shpall1, Uday R Popat1, Richard E Champlin1, Stefan O Ciurea2.   

Abstract

Fluid overload (FO) commonly occurs during hospitalization for allogeneic hematopoietic stem cell transplantation. We hypothesized that FO is associated with transplantation outcomes and evaluated this complication in 2 cohorts of patients. FO was graded based on post-transplantation weight gain, symptoms, and need for treatment, scored in real time by an independent team. The first cohort (study cohort; n = 145) underwent haploidentical transplantation for hematologic malignancies following a melphalan-based conditioning regimen. In univariate analysis, factors associated with day +100 nonrelapse mortality (NRM) were FO grade ≥2 (hazard ratio [HR], 15; 95% confidence interval [CI], 4.2 to 55; P < .001), creatinine >1 mg/dL (HR, 4.7; 95% CI, 1.6 to 14; P = .005), and age >55 years (HR, 4.5; 95% CI, 1.5 to 13; P = .008). In multivariate analysis, factors associated with day +100 NRM were FO grade ≥2 (HR, 13.1; 95% CI, 3.4 to 50; P < .001) and serum creatinine level >1 mg/dL at transplantation admission (HR, 3.5; 95% CI, 1.1 to 11; P = .03). These findings were verified in a separate cohort (validation cohort) of patients with acute myelogenous leukemia/myelodysplastic syndrome who underwent HLA-matched transplantation with busulfan-based conditioning (n = 449). In multivariate analysis, factors associated with day +100 NRM were FO grade ≥2 (HR, 34; 95% CI, 7.2 to 158; P < .001) and, in patients with FO grade <2, advanced disease status (HR, 5; 95% CI, 1.1 to 22; P = .03). A higher NRM translated to significantly poorer 1-year overall survival rates for patients with FO ≥2 than for patients without FO (70% versus 42%, P < .001 in the study cohort and 64% versus 38%, P < .001 in the validation cohort). In conclusion, FO grade ≥2 is strongly associated with higher NRM and shorter survival and should be considered an important prognostic factor in transplantation.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic stem cell transplantation; Fluid overload; Fluid retention; Fluid toxicity; Haploidentical transplantation; Nonrelapse mortality; Weight gain

Mesh:

Year:  2017        PMID: 28844946      PMCID: PMC5889108          DOI: 10.1016/j.bbmt.2017.08.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

1.  Serial assessment of toxicity after hematopoietic SCT can discern kinetics of transplant-related organ injury and patterns of recovery.

Authors:  A Chou; M Guo; J Tay; H Atkins; I Bence-Bruckler; M Sabloff; L Huebsch; D Allan
Journal:  Bone Marrow Transplant       Date:  2012-03-05       Impact factor: 5.483

Review 2.  Fluid Overload.

Authors:  Michael E O'Connor; John R Prowle
Journal:  Crit Care Clin       Date:  2015-07-29       Impact factor: 3.598

Review 3.  Acute complications of stem cell transplant.

Authors:  Chris Rimkus
Journal:  Semin Oncol Nurs       Date:  2009-05       Impact factor: 2.315

4.  Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.

Authors:  Sameh Gaballa; Isabell Ge; Riad El Fakih; Jonathan E Brammer; Piyanuch Kongtim; Ciprian Tomuleasa; Sa A Wang; Dean Lee; Demetrios Petropoulos; Kai Cao; Gabriela Rondon; Julianne Chen; Aimee Hammerstrom; Lindsey Lombardi; Gheath Alatrash; Martin Korbling; Betul Oran; Partow Kebriaei; Sairah Ahmed; Nina Shah; Katayoun Rezvani; David Marin; Qaiser Bashir; Amin Alousi; Yago Nieto; Muzaffar Qazilbash; Chitra Hosing; Uday Popat; Elizabeth J Shpall; Issa Khouri; Richard E Champlin; Stefan O Ciurea
Journal:  Cancer       Date:  2016-07-12       Impact factor: 6.860

5.  Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

Authors:  John T Horan; Brent R Logan; Manza-A Agovi-Johnson; Hillard M Lazarus; Andrea A Bacigalupo; Karen K Ballen; Christopher N Bredeson; Matthew H Carabasi; Vikas Gupta; Gregory A Hale; Hanna Jean Khoury; Mark B Juckett; Mark R Litzow; Rodrigo Martino; Philip L McCarthy; Franklin O Smith; J Douglas Rizzo; Marcelo C Pasquini
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Regimen-related toxicity in patients undergoing bone marrow transplantation.

Authors:  S I Bearman; F R Appelbaum; C D Buckner; F B Petersen; L D Fisher; R A Clift; E D Thomas
Journal:  J Clin Oncol       Date:  1988-10       Impact factor: 44.544

7.  Reduced mortality after allogeneic hematopoietic-cell transplantation.

Authors:  Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

8.  Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Authors:  Gheath Alatrash; Marcos de Lima; Nelson Hamerschlak; Matteo Pelosini; Xuemei Wang; Lianchun Xiao; Fabio Kerbauy; Alexandre Chiattone; Gabriela Rondon; Muzaffar H Qazilbash; Sergio A Giralt; Leandro de Padua Silva; Chitra Hosing; Partow Kebriaei; Weiqing Zhang; Yago Nieto; Rima M Saliba; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-18       Impact factor: 5.742

Review 9.  Patient-reported outcomes and the evolution of adverse event reporting in oncology.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Ethan Basch
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

  9 in total
  13 in total

1.  Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.

Authors:  Carlos Rondon-Clavo; Michael Scordo; Patrick Hilden; Gunjan L Shah; Christina Cho; Molly A Maloy; Esperanza B Papadopoulos; Ann A Jakubowski; Richard J O'Reilly; Boglarka Gyurkocza; Hugo Castro-Malaspina; Roni Tamari; Brian C Shaffer; Miguel-Angel Perales; Edgar A Jaimes; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2018-07-26       Impact factor: 5.742

2.  Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data.

Authors:  Daniel Teschner; Jana Knop; Christian Piehl; Sophia Junker; Oliver Witzke
Journal:  Infection       Date:  2022-05-28       Impact factor: 3.553

Review 3.  Lung Ultrasound versus Chest X-Ray for the Detection of Fluid Overload in Critically Ill Children: A Systematic Review.

Authors:  Emily Schapka; Jerica Gee; John W Cyrus; Gregory Goldstein; Kara Greenfield; Mark Marinello; Oliver Karam
Journal:  J Pediatr Intensive Care       Date:  2021-03-23

4.  Risk factors for severe acute kidney injury after pediatric hematopoietic cell transplantation.

Authors:  Abbie Bauer; Kristen Carlin; Stephen M Schwartz; Meera Srikanthan; Monica Thakar; Lauri M Burroughs; Jodi Smith; Sangeeta Hingorani; Shina Menon
Journal:  Pediatr Nephrol       Date:  2022-09-20       Impact factor: 3.651

5.  Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.

Authors:  Kimberley Joanne Hatfield; Øystein Bruserud; Håkon Reikvam
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

6.  Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.

Authors:  Mithun Vinod Shah; Rima M Saliba; Gabriela Rondon; Julianne Chen; Doris Soebbing; Ioana Rus; Amin Alousi; Betul Oran; Partow Kebriaei; Muzaffar Qazilbash; Simrit Parmar; Chitra Hosing; Issa F Khouri; Uday R Popat; Richard E Champlin; Stefan O Ciurea
Journal:  Bone Marrow Transplant       Date:  2018-10-18       Impact factor: 5.483

7.  Early bilirubinemia after allogeneic stem cell transplantation-an endothelial complication.

Authors:  Hao Dai; Olaf Penack; Aleksandar Radujkovic; David Schult; Joshua Majer-Lauterbach; Igor Wolfgang Blau; Lars Bullinger; Sihe Jiang; Carsten Müller-Tidow; Peter Dreger; Thomas Luft
Journal:  Bone Marrow Transplant       Date:  2021-01-30       Impact factor: 5.483

Review 8.  Continuous Renal Replacement Therapy: A Review of Use and Application in Pediatric Hematopoietic Stem Cell Transplant Recipients.

Authors:  Lama Elbahlawan; John Bissler; R Ray Morrison
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

9.  Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients.

Authors:  K J Skaarud; M B Veierød; S Lergenmuller; A Bye; P O Iversen; G E Tjønnfjord
Journal:  Bone Marrow Transplant       Date:  2019-08-27       Impact factor: 5.483

10.  Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy.

Authors:  Olivier Ballo; Fagr Eladly; Sebastian Koschade; Stefan Büttner; Jan Alexander Stratmann; Uta Brunnberg; Eva-Maria Kreisel; Franziska Frank; Sebastian Wagner; Björn Steffen; Hubert Serve; Fabian Finkelmeier; Christian H Brandts
Journal:  Ann Hematol       Date:  2021-07-25       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.